Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Breast Cancer

Prognostic stratification of metastatic triple-negative breast cancer patients using PET-radiomic features from malignant and tumor-free regions

Auriac Julie, Mathilde Droguet, Lalith Kumar Shiyam Sundar, Romain-David Seban, Marie Luporsi, Manuel Pires, Christophe Nioche, Thomas Beyer, François-Clément Bidard, Irene Buvat and Fanny ORLHAC
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241952;
Auriac Julie
1Institut Curie, Inserm, Université PSL, U1288 LITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathilde Droguet
1Institut Curie, Inserm, Université PSL, U1288 LITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lalith Kumar Shiyam Sundar
2Medical University of Vienna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romain-David Seban
3Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Luporsi
4Curie Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Pires
5Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Nioche
3Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Beyer
2Medical University of Vienna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François-Clément Bidard
6Institut Curie, Department of Medical Oncology, Paris-Saint-Cloud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Buvat
7LITO, Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanny ORLHAC
8LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

241952

Introduction: In oncology, most radiomic studies focus on tumor lesions only, ignoring potentially useful signal present in non-tumor regions. However, recent studies suggested that the metabolic activity outside the lesion could include valuable information for predicting overall survival (OS) in cancer patients. We investigated whether the combination of clinical and radiomic features from whole-body [18F]FDG-PET images, including malignant and tumor-free regions, could predict OS in metastatic triple negative breast cancer (TNBC) patients.

Methods: Baseline whole-body [18F]FDG-PET/CT images acquired before any treatment and clinical data were collected for 122 metastatic TNBC patients with at least 24 months of follow-up. All tumor lesions were automatically segmented in the PET images using the AI-driven automated segmentation tool LION (). Lesion delineation was then refined using a standardized uptake value (SUV) threshold of 4. The resulting regions were used to calculate the Total Metabolic Tumor Volume (TMTV) and the distance between the 2 most distant lesions (Dmax) with LIFEx v.7.4.2 [Nioche et al. Cancer Res. 2018]. Using MOOSE v.2.3.5 [Shiyam Sundar et al. J Nucl Med. 2022] and TotalSegmentator v.2.0.5 [Wasserthal et al. Radiology: Artificial Intelligence. 2023], six anatomical structures (subcutaneous fat, muscles, pancreas, spinal cord, spleen, and thyroid) were automatically segmented on the CT of the PET/CT scan. The mean SUV normalized by lean body mass (SULmean) [Sugawara, et al. Radiology, 1999] was computed for each anatomical compartment, except the subcutaneous fat. We also calculated the mean Hounsfield Units (HUmean) and the volumes for the subcutaneous fat and the muscles. All 11 radiomic feature values, as well as the patient age and body mass index (BMI), were dichotomized using cut-off values that maximized the log-rank test statistic for OS. Using a stepwise algorithm with the Akaike Information Criteria (AIC), we identified a Cox multivariable model for OS based on clinical features, TMTV and Dmax (called M1) or based on clinical variables and all 11 radiomic features extracted from non-/malignant regions (M2). For each model, the patients were stratified into 3 groups that led to the highest Harrell’s Concordance-index (C-index). The 1-year, 2-year and 3-year OS rates for each survival profile were reported.

Results: The multivariable model M1 (C-index = 0.73) included the 4 proposed features: older patients (> 45y), with a high dissemination of lesions (Dmax > 56cm), high TMTV (> 167 mL) and low BMI (< 22.6 kg.m-2) were associated with a poor OS (Table 1). When including radiomic features measured outside the lesions, the model M2 (C-index = 0.77) consisted of 7 features: a high dissemination of lesions, high TMTV, high FDG-uptake in muscles (SULmean > 0.5), low FDG-uptake in spinal cord (SULmean < 0.9), low FDG-uptake in spleen (SULmean < 1), low FDG-uptake in thyroid (SULmean < 0.7) and low volume of muscles (< 7,239 mL) were associated with a poor OS. Model M2 led to a better stratification of patients into 3 risk groups compared to model M1, by identifying both a group of patients with a very good prognosis (57 low-risk patients; 1y-OS rate: 95%, 2y: 84%, 3y: 78%, Figure 1) and a group with a very poor prognosis (24 high-risk patients; 1y: 63%, 2y: 8%, 3y: 0%). Forty-one patients were classified as intermediate-risk patients (1y: 90%, 2y: 49%, 3y: 25%).

Conclusions: Our findings suggest that the addition of radiomic features measured outside the lesion, in combination with clinical data, TMTV and Dmax, leads to a better stratification of TNBC patients according to OS, and helps identify patients with a very good or very poor prognosis. Further investigations are needed to understand the relationship between these features and patient survival, and to validate these results in an independent cohort.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic stratification of metastatic triple-negative breast cancer patients using PET-radiomic features from malignant and tumor-free regions
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prognostic stratification of metastatic triple-negative breast cancer patients using PET-radiomic features from malignant and tumor-free regions
Auriac Julie, Mathilde Droguet, Lalith Kumar Shiyam Sundar, Romain-David Seban, Marie Luporsi, Manuel Pires, Christophe Nioche, Thomas Beyer, François-Clément Bidard, Irene Buvat, Fanny ORLHAC
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241952;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic stratification of metastatic triple-negative breast cancer patients using PET-radiomic features from malignant and tumor-free regions
Auriac Julie, Mathilde Droguet, Lalith Kumar Shiyam Sundar, Romain-David Seban, Marie Luporsi, Manuel Pires, Christophe Nioche, Thomas Beyer, François-Clément Bidard, Irene Buvat, Fanny ORLHAC
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241952;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 18F-AlF-LNC1007 in the evaluation of Breast cancer:comparison with 18F-FDG/18F-FAPI-04 PET/CT
  • FAPI Versus 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer
  • Gallium-68-NeoB PET in Breast Cancer Patients: First results from a Prospective Observational Trial
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Breast Cancer

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire